Spots Global Cancer Trial Database for hl
Every month we try and update this database with for hl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | NCT01393106 | Hodgkin Lymphom... | Idelalisib | 12 Years - | Gilead Sciences | |
| Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | NCT00439361 | Hodgkin Lymphom... Lymphoma | Bortezomib Carboplatin Etoposide Ifosfamide Mesna | 16 Years - | M.D. Anderson Cancer Center | |
| Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | NCT02247869 | Hodgkin Lymphom... | dose dense ABVD | 18 Years - 70 Years | Fondazione Italiana Linfomi - ETS | |
| Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | NCT02247869 | Hodgkin Lymphom... | dose dense ABVD | 18 Years - 70 Years | Fondazione Italiana Linfomi - ETS | |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | NCT02169505 | Lymphoma | Brentuximab Ved... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD | NCT02298283 | Hodgkin Lymphom... | brentuximab ved... Cyclophosphamid... Adriamycin Oncovin Bleomycin Etoposide Procarbazine Prednisone G-CSF 30 Grays | 18 Years - 65 Years | The Lymphoma Academic Research Organisation | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | NCT01393106 | Hodgkin Lymphom... | Idelalisib | 12 Years - | Gilead Sciences | |
| Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | NCT02243436 | CLASSICAL HODGK... | Brentuximab Ved... Etoposide Soludomerin Cisplatin Ara C | 18 Years - | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas | NCT02763254 | Hodgkin Lymphom... Lymphoma, Large... Post-transplant... | baltaleucel-T | 12 Years - | Cell Medica Ltd | |
| Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. | NCT02292979 | Hodgkin Lymphom... | Doxorubicin Bleomycin Vinblastine Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | The Lymphoma Academic Research Organisation | |
| Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | NCT02065154 | Leukemia Lymphoma Myelodysplastic... Myelofibrosis Severe Aplastic... Allogeneic Tran... | Cyclophosphamid... | 19 Years - 65 Years | University of Alabama at Birmingham | |
| Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | NCT02065154 | Leukemia Lymphoma Myelodysplastic... Myelofibrosis Severe Aplastic... Allogeneic Tran... | Cyclophosphamid... | 19 Years - 65 Years | University of Alabama at Birmingham | |
| Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | NCT02243436 | CLASSICAL HODGK... | Brentuximab Ved... Etoposide Soludomerin Cisplatin Ara C | 18 Years - | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | NCT02223052 | Hematological N... Non-Hodgkin's L... Hodgkin's Lymph... Lymphoma Multiple Myelom... Acute Myeloid L... Leukemia Myelodysplastic... Neoplasms Melanoma Breast Cancer Metastatic Brea... Non-Small Cell ... Small Cell Lung... Renal Cell Carc... Glioblastoma Mu... Osteosarcoma Sarcoma Thyroid Cancer Genitourinary | CC-486 Vidaza | 18 Years - | Celgene | |
| Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma | NCT00742027 | Classical Hodgk... | Panobinostat | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
